Managing Antiplatelet Therapy in Patients with Acute Coronary Syndrome

Published Online: Monday, March 25, 2013
Follow Pharmacy_Times:
In this podcast, Toby Trujillo, PharmD, BCPS, an associate professor at the University of Colorado Denver School of Pharmacy, discusses issues related to options for managing antiplatelet therapy in patients with acute coronary syndrome. To listen to the podcast, click here.
Related Articles
Many cardiologists and pharmacists are concerned about clopidogrel, especially when it is prescribed for patients with diabetes.
For the first time, one antiplatelet agent has been recommended over another for non–ST-segment elevation acute coronary syndrome.
Patients who receive statins soon after acute coronary syndrome are 24% less likely to experience unstable angina after 4 months.
Patients continue to benefit from high-dose atorvastatin therapy for at least 5 years after acute coronary syndrome, according to a new study.
Latest Issues
$auto_registration$